Survival outcomes of patients treated with axi-cel for PMBCL or DLBCL. (A) PFS and (B) OS of patients treated with axi-cel for PMBCL or DLBCL. PFS according to LDH status (elevated vs normal LDH) for (C) PMBCL and (D) DLBCL; and response to bridging therapy (response vs nonresponse) for (E) PMBCL and (F) DLBCL, as assessed at lymphodepletion among patients with PMBC and DLBCL treated with axi-cel. HR, hazard ratio; LDH, lactate dehydrogenase; mo, month; N, normal.